Net open-market buying, 180d$78K · 76 pct, sector of 67
Insider buyers, 180d1 · 65 pct, sector of 67
Risk and compliance
36
Inputs
Short interest, % of float+7.6% · 36 pct, sector of 95
Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
5 not measured: Profitability, Financial health, Growth, Institutional and government, US patents
Profitability needs 2 of 4 inputs, 0 present: fewer than four consecutive quarters of net income; fewer than four consecutive quarters of operating income
Financial health needs 1 of 2 inputs, 0 present: needs four quarters of operating cash flow; no equity line filed
Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet
2 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
What the filings say about STLN
In the 180 days to 2026-10-12, Starling Oncology insiders were net sellers of STLN, a net $1.9M across purchases and sales reported on Form 4 by 1 buyer and 1 seller. Sales outweighed purchases more than tenfold by value. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-12, covering $2.0M of stock. Each figure is counted from SEC and House filings as of 2026-10-12, dated the day the filing was made public.
STLN filings FAQ
Are Starling Oncology insiders buying or selling STLN?
In the 180 days to 2026-10-12, Starling Oncology insiders were net sellers, a net $1.9M: $78.5K of purchases and $1.9M of sales reported on Form 4, by 1 buyer and 1 seller.
Are there planned insider sales of STLN?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-12, covering $2.0M of stock; the latest, by BRADFORD HIVELY, was filed 2026-08-21.
-$1.9M over 90 days · +$78.5K of it by a 10%+ holder
below 53% of Healthcare Services
Congress
no Congress trades reported
Funds
under five funds report holding it
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
7.6% of the float short (float per yahoo 2026-10-09) · 4.3 days to cover · settled 2026-09-30
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch STLN
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+73.6%12M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $1.9M sold by insiders over 180 days, $2.0M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Starling Oncology, Inc. insiders sold a net $1.9M of stock across 2 Form 4 purchases and sales, with 1 insider(s) buying. Source: SEC Form 4 filings, as of 2026-10-12.
First open-market trade here by this insider on our record.
The trade is 72.5% of the 411,976 shares held after it.
No other insider sold within 30 days.
Insider activity: Director Hively Brad sold about $1.9M of STLN under a 10b5-1 plan on Aug 21, 2026, the largest insider sale at the company on our record.
First open-market trade here by this insider on our record.
The trade is 0.1% of the 10,660,858 shares held after it.
No other insider bought within 30 days.
Insider activity: Insider Chernett Jorey bought about $78.5K of STLN on the open market on Aug 14, 2026, the largest insider purchase at the company on our record.
2 transactions on record · a thin record, read with care
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Nobody has filed for crossing 5%. That is a fact, not missing data.
STLN planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
BRADFORD HIVELY
Filed 2026-08-21
$2.0M
Executive pay vs shareholder return · Daniel Virnich
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$1.9M
$8.0M
$755.0K
+75%
n/a
2024
$1.1M
-$510.6K
$522.4K
-85%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
No password to create and no card required. We store your email address and nothing else.
PRIVACY & COOKIES
We track filings, not you.
Essential cookies keep you signed in. Google Analytics and
Microsoft Clarity load only if you allow them here, to show us which datasets matter.
No ad trackers, ever. Details in the privacy
policy.
